Effect of exenatide on fat deposition and a metabolic profile in patients with metabolic syndrome.
BACKGROUND
The aim of this study was to evaluate the effect of exenatide on fat deposition and a metabolic profile in patients with metabolic syndrome.


METHODS
An uncontrolled, open clinical study was carried out in 10 patients with metabolic syndrome and without pharmacological treatment. Patients received exenatide (5 μg) subcutaneously twice daily for 1 month. Before and after the intervention, metabolic profile and phases of insulin secretion and insulin sensitivity were estimated. To assess insulin secretion and sensitivity, the hyperglycemic-hyperinsulinemic clamp technique was performed. Computed tomography was performed to evaluate both subcutaneous and visceral fat. The Wilcoxon signed-rank test and Mann-Whitney U-test were used for statistical analyses.


RESULTS
Weight, body mass index, waist circumference, and systolic blood pressure were decreased by exenatide. Subcutaneous fat deposition decreased by 4.4% compared to the basal value. There were significant decreases in total cholesterol and low-density lipoprotein cholesterol, as well as an increment in the first phase of insulin secretion after the intervention.


CONCLUSIONS
One-month administration of exenatide significantly decreased subcutaneous fat deposition by 4.4%, improving the metabolic profile in patients with metabolic syndrome.
González-Ortiz
Manuel
M
Cardiovascular Research Unit, Physiology Department, Health Science University Center, University of Guadalajara, Mexico. uiec@prodigy.net.mx
Martínez-Abundis
Esperanza
E
Robles-Cervantes
José A
JA
Ramos-Zavala
Maria G
MG
D000273:Adipose Tissue / Q000187:drug effects* / Q000378:metabolism; D000328:Adult; D050218:Body Fat Distribution; D004334:Drug Administration Schedule; D000077270:Exenatide; D005260:Female; D006801:Humans; D007004:Hypoglycemic Agents / Q000008:administration & dosage / Q000494:pharmacology; D007279:Injections, Subcutaneous; D008055:Lipids / Q000097:blood; D008297:Male; D024821:Metabolic Syndrome / Q000188:drug therapy / Q000378:metabolism*; D055442:Metabolome / Q000187:drug effects*; D010455:Peptides / Q000008:administration & dosage / Q000494:pharmacology*; D014688:Venoms / Q000008:administration & dosage / Q000494:pharmacology*; D055815:Young Adult
D007004:Hypoglycemic Agents; D008055:Lipids; D010455:Peptides; D014688:Venoms; D000077270:Exenatide